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http:WHAT THIS PAPER ADDS?
This is the ﬁrst study to use a whole genomic approach to analyse the gene expression proﬁle of histologically
unstable carotid atherosclerotic plaques compared to stable plaques in neurologically asymptomatic patients.
We have demonstrated in asymptomatic patients as previously shown in symptomatic patients that patients
with histologically unstable plaques have altered expression of genes related to inﬂammation and immune
response. The altered gene expression proﬁle found may lead to changes in chemokine signalling and plaque
rupture. Novel gene clusters related to intra-cellular signalling and alterations in transcription identiﬁed from
this study are potential areas for further research.Background: Many studies have evaluated histological and gene expression proﬁles in TIA/stroke patients after
onset of symptoms, but there is limited understanding as to how these plaque related features interact before
symptom onset. In particular, no studies have evaluated differential gene expression in histologically unstable (vs
stable plaques) in neurologically asymptomatic patients.
Methods: Nine asymptomatic patients had their plaques scored blindly by two independent Histopathologists
using the AHA plaque scoring system. RNA extracted from the plaques was hybridised onto a whole genome
microarray. Analysis was performed using GenomeStudio (v1.0) and the DAVID bioinformatics resource (v6.7).
Results: Three plaques were histologically unstable (Grade 2/3), while six were stable (Grade 0/1). 346
differentially expressed genes (>1.3 fold, P < 0.05) were identiﬁed (293 down-regulated and 53 up-regulated)
between stable and unstable plaques. Genes related to chemokine and protein signalling (pro-inﬂammatory/pro-
apoptotic) were identiﬁed to have high enrichment scores (>1.3) and were signiﬁcantly up-regulated in unstable
(asymptomatic) plaques.
Conclusion: The ﬁndings conﬁrm the intuitively held belief that changes in chemokine and protein signalling may
be associated with acute plaque disruption and precede the onset of symptoms. Once validated, these genes
could therefore become targets for innovative medical treatments in the future or could help identify
asymptomatic patients with histologically unstable plaques that would beneﬁt from surgical intervention.
 2012 European Society for Vascular Surgery. European Society for Vascular Surgery. Published by Elsevier Ltd.
All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2012.11.006unstable carotid atherosclerotic plaques.1 Instability is
characterised by a large lipid core and plaque inﬂammation,
leading to cap rupture, surface ulceration and thrombus
formation. The pathogenesis of plaque instability is poorly
understood but is thought to result from a combination of
altered gene expression in conjunction with local and
systemic inﬂammation.
Guidelines exist for the management of patients with
symptomatic carotid stenosis2e5 however with increasing
evidence that advanced and aggressive medical therapy is
reducing the annual risk of stroke in patients with asymp-
tomatic stenosis,6,7 guidelines for intervention in
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However; a small but important cohort of patients with
asymptomatic carotid disease will go on to suffer a stroke. It
would, therefore, be very beneﬁcial to identify these
patients who might then beneﬁt from intervention.
To date, few gene-proﬁling studies have been performed
in asymptomatic patients where the proﬁling is correlated
with histological patterns of plaque instability; i.e. in
patients who have not yet reported neurological symptoms.
Our hypothesis was that asymptomatic patients with
histologically unstable plaques would have an altered gene
expression proﬁle compared to histologically stable plaques
from asymptomatic patients. If true, this would open up
a new means of developing novel management strategies in
asymptomatic patients with carotid disease.
METHODS
Patient selection
Further information is available the Online Data
Supplement.
Asymptomatic patients were included in the study if they
were undergoing carotid endarterectomy (CEA) in the
presence of a 70e99% carotid stenosis (NASCET) using
colour duplex imaging. Prior to surgery, all patients were
commenced on statin therapy (Simvastatin 40 mg daily),
antiplatelet therapy (Aspirin 75 mg daily) and antihyper-
tensive therapy as appropriate (unless contraindicated). In
addition 75 mg clopidogrel was given the night before
surgery.9 30 min of TCD monitoring was performed and
recorded using the Consensus Committee Criteria.10
This study was authorised by the Leicestershire, North-
amptonshire and Rutland Ethics Committee and all partici-
pants gave informed consent.Data collection
Pre-operative clinical data were recorded by a single inves-
tigator (MS) through face to face questioning of patients and
following review of medical notes and in-patient investiga-
tions. Demographic data recorded included; age, sex,
vascular risk factors (hypertension, hyperlipidaemia, dia-
betes mellitus and smoking) and pre-operative medication.Carotid endarterectomy
Carotid Endarterectomy was performed under general
anaesthesia with routine patching, routine shunting,
systemic heparinisation (unfractionated) and distal intimal
tacking sutures.11 Endarterectomy was performed via
a linear arteriotomy and the plaque removed with the
minimum of trauma possible.Figure 1. Stable plaque on H&E staining showing intact cap (C) and
predominantly ﬁbrous tissue (FT) and underlying intima (I) (10).Sample processing
See Online Data Supplement.
RNA extraction from carotid plaques
See Online Data Supplement.Histopathology
See Online Data Supplement for further information.
Histological specimens were analysed independently by
two histopathologists (KW, DM) who were blinded to clin-
ical and demographic data.
Histological features
See Figs. 1 and 2. For each plaque, a semi-quantitative 3 or
4 point score (Table 1) was assigned to show the presence
and/or amount of features of plaque instability based on
the AHA histological classiﬁcation of advanced atheroscle-
rotic lesions12 and a well validated previously published
scoring system.13 Features analysed included; intra-plaque
haemorrhage, haemosiderin deposition, surface thrombus,
lipid core size, nodular calciﬁcation, proportion of ﬁbrous
tissue, acute and chronic plaque inﬂammatory inﬁltrate,
acute and chronic cap inﬂammatory inﬁltrate, neo-
vascularity, amount of foam cells, and evidence of cap
rupture. Intra-plaque haemorrhage was deﬁned as evidence
of erythrocytes within the plaque causing disruption of
plaque architecture as deﬁned by Bassiouny.14 Surface
thrombus was deﬁned as the presence of an organised
collection of ﬁbrin and red blood cells in the lumen as
demonstrated by Lammie.15 Lipid core was deﬁned as an
area of amorphous material containing cholesterol clefts.
Rupture was deﬁned as a clear communication between
lipid core and lumen with a break in the ﬁbrous cap.
Calciﬁcation was identiﬁed through evidence of nodular
deposits.
Based upon the score for each of these features in each
plaque an overall stability rating was given by the histo-
pathologists as ‘stable’ or ‘unstable’. Unstable plaques
demonstrated many or all of these features whilst stable
plaques demonstrated none, allowing for direct comparison
between two groups.
Gene expression analysis
Further information on the methods is available in the
Supplementary Data.
Figure 2. Unstable plaque on H&E staining showing cap rupture
(arrow), intraplaque haemorrhage (IPH) and surface thrombus
(ST) (10).
M.K. Salem et al. 123Brieﬂy, gene expression study microarray analysis was
performed using Illumina cDNA-mediated Annealing,
Selection, extension and Ligation (DASL) assay which allows
for expression proﬁling of partially degraded RNA and
covers approximately 24,000 genes. Detailed descriptions of
all data and protocols were submitted to the ArrayExpress
public repository (http://www.ebi.ac.uk/miamexpress/
login.htm, accession number: E-MEXP-3683) as per MIAMI
guidelines.16 Genes differentially expressed were identiﬁed
by ﬁltering, using the following criteria: (1) an Illumina diff
score greater than 13 or less than 13 (equivalent to a P
value <0.05) and (2) a 1.3-fold difference in the mean signal
between groups in each separate analysis.
Hierarchical clustering, gene-class testing and KEGG
pathway analysis for functional pathways and gene
ontology (GO) categories was performed by using DAVID
software.17 Gene class testing and clustering is an explor-
atory tool for looking at associations within gene expression
data and allows for hypothesis generation and selection of
genes for further consideration. Gene ontology is a bio-
informatics initiative to unify representation of gene and
gene products across species. Gene ontology covers three
domains; 1. Cellular component, the parts of a cell or its
extracellular environment; 2. Molecular function, the
elemental activities of a gene product at the molecular level
and 3. Biological process, operations or sets of molecularTable 1. Semi-quantitative scoring system for histological.
Histological Feature Grade 0 Grade 1
Haemorrhage No haemorrhage Small ha
Lipid core No lipid core Small lip
Chronic plaque inﬂammation None Occasion
one gr
Chronic cap inﬂammation None <10 cel
Foam cells None <50 cel
Neovascularity None <10/sec
Cap rupture Intact Probably
Overall stability Stableevents with a deﬁned beginning and end, pertinent to the
functioning of integrated living units: cells, tissues, organs,
and organisms. KEGG pathway analysis is used to assess
which pathways are over-represented in a given set of
genes. This allows for identiﬁcation of pathways affected by
sets of genes which have altered expression.
Statistical analysis
Microarray study analysis was performed according to
current guidelines using Illumina GenomeStudio (v1) soft-
ware. T-Test and c2 was used to compare baseline charac-
teristics between patients in each group. Statistical analysis
was performed using SPSS v16 (Chicago, USA).
RESULTS
Between March 2009 and December 2009, 18 consecutive
patients undergoing carotid endarterectomy for asymp-
tomatic carotid artery stenosis were recruited into the
study. Nine patients were excluded as RNA quality {RNA
Integrity Number (RIN) <5} was not suitable for microarray
study.
Out of the nine remaining patients, three were classed as
unstable and six were deﬁned as stable based upon histo-
logical criteria (Table 2).
Gene expression studies
Comparing the stable and the unstable plaques, 346
differentially expressed genes (>1.3 fold, P < 0.05) were
identiﬁed. Of these 293 were down-regulated and 53 were
up-regulated (Supplementary Table 1).
Functional annotation clustering. The signiﬁcantly differ-
entially expressed genes contributed to four functional
annotation clusters with an enrichment score greater than
1.3 (Table 3). These functional annotation clusters relate to
SH2 motif and domain, which are involved in intracellular
signalling; biological processes involved in response to
wounding and inﬂammation; biological processes involved
in protein maturation, processing and cleavage; and cellular
components related to the endoplasmic reticulum.
Gene ontology (GO) processes.When genes were analysed
according to the GO processes, the differentially expressed
genes contributed to 35 different GO biological processes,
14 different GO molecular functions and 8 different GOGrade 2 Grade 3
emorrhage Large haemorrhage e
id core Large lipid core e
al cells or
oup >50
2e5 groups >50 >5 groups >50 or
1 group >500
ls in cap 10e50 cells in cap >50 cells in cap
ls >50 cells e
tion >10/section e
intact Probably ruptured Deﬁnitely ruptured
Unstable
Table 2. Demographics for asymptomatic patients presenting with
stable/unstable plaques.
Patient demographics Stable plaque
(n ¼ 6)
Unstable plaque
(n ¼ 3)
P
value
Male 5 (83%) 2 (67%) 1
Female 1 (17%) 1 (33%)
Age (median) 70 (53e75) 64 (60e71) 0.74
Hypertension 5 (83%) 2 (67%) 0.8
Hypercholesterolaemia 4 (67%) 2 (67%) 1
Diabetes mellitus 1 (17%) 0 (0%) 1
Ischaemic heart disease 1 (17%) 0 (0%) 1
Ex/current smoker 6 (100%) 2 (67%) 0.33
On anti-platelet therapy 6 (100%) 3 (100%) 1
On statin therapy 6 (100%) 3 (100%) 1
Evidence of spontaneous
embolisation during
TCD monitoring
1 (17%) 1 (33%) 1
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expressed genes annotated under each of these GO
processes varied from 2 to 55. The top 10 GO biological
processes involved transcription, regulation of transcription,
polymerase II promoter, response to wounding, immune
response, response to wounding, vesicle mediated trans-
port, defence response, protein kinase cascade and
inﬂammatory response.
Kegg pathway analysis. Differentially expressed genes were
identiﬁed to contribute to the chemokine signalling and
spliceosome pathway.Table 3. Functional annotation clustering e enrichment scores.
Term Count P-value Benjamini
Enrichment score 1.7
RT 9 9.40E  03 9.90E  01
SH2 motif 7 1.70E  02 1.00E þ 00
SH2 7 2.00E  02 9.50E  01
SH2 domain 6 6.00E  02 9.00E  01
Enrichment score 1.5
Response to wounding 18 1.60E  02 1.00E þ 00
Immune response 20 2.50E  02 1.00E þ 00
Defence response 18 5.40E  02 9.90E  01
Inﬂammatory response 11 7.40E  02 9.90E  01
Enrichment score 1.3
Protein maturation 8 6.00E  03 1.00E þ 00
Protein processing 6 4.80E  02 9.90E þ 00
Protein maturation by
peptide bond cleavage
3 4.50E  01 1.00 þ 00
Enrichment score 1.3
Endoplasmic reticulum
lumen
6 2.30E  02 1.00E þ 00
Short sequence motif:
prevents secretion
from ER
5 2.70E  02 1.00E þ 00
Protein folding 8 3.10E  02 1.00E þ 00
Endoplasmic reticulum,
targeting sequence
4 5.00E  02 1.00E þ 00
Isomerase 6 7.20E  02 9.00E  01
Endoplasmic reticulum
part
10 2.70E  01 9.80E  01DISCUSSION
This is the ﬁrst study to evaluate the gene expression proﬁle
of carotid atherosclerotic plaques harvested during carotid
endarterectomy from asymptomatic patients with histo-
logically stable as opposed to histologically unstable pla-
ques. Histologically unstable features (traditionally seen in
recently symptomatic patients) include; plaque haemor-
rhage, marked cap and plaque inﬂammation, large lipid
core, surface thrombus, marked vascularity, many foam cells
and cap rupture. Histologically stable plaques that did not
demonstrate these features were chosen as the control as
this would allow for direct comparison in gene expression
proﬁles.
This study used a whole genome approach to charac-
terise the gene-expression proﬁle of the histologically
unstable asymptomatic plaque compared to the histologi-
cally stable asymptomatic plaque. 346 differentially
expressed genes were identiﬁed. Expression of the majority
of genes (293) was decreased, whilst expression of 53 genes
was increased.
Using functional gene clustering and gene ontology terms
we were able to identify clusters of genes involved in
intracellular signalling, response to wounding and inﬂam-
mation, protein maturation, transcription and protein
kinase cascade.
KEGG pathways analysis allowed us to identify eight
genes involved in the chemokine signalling pathway and six
genes involved in the spliceosome pathway.
Previous studies using microarray in a similar number of
specimens have compared plaques from symptomatic against
asymptomatic.18e23 Papaspyridonos et al.24 looked at histo-
logically ‘stable’ vs ‘unstable’ plaques but samples included
patients who were both symptomatic and asymptomatic.
Previous microarray studies comparing carotid athero-
sclerotic plaques in symptomatic and histologically ‘unstable’
plaques have alluded to the role of angiogenesis,23 including
hypoxia driven angiogenesis,25 inﬂammation,18,19 cytokine
and chemokine signalling,26 apoptosis,27,28 alterations in
lipid metabolism,21,22 osteogenesis,28,29 proteolysis and
collagenolysis,29 and changes in iron metabolism in plaque
progression.20
This study further adds evidence regarding the role of
altered expression of genes related to inﬂammation,
proteolysis and chemokine signalling, but also suggests an
additional role for disturbances in transcription, spliceo-
some pathway and cellular components related to the
endoplasmic reticulum. As the majority of the genes are
down-regulated 293/346 (85%) it is likely that down-regu-
lation of many of the genes identiﬁed are contributing to
plaque instability. It is also possible that varying degrees of
altered gene expression can cause variable plaque
instability.
The limitations of this study are that whole plaque
specimens were used in all experiments. The purpose of this
was that historical gene expression studies in carotid pla-
ques have evaluated subgroup cell types and populations,
and by avoiding this targeted selection of cells we have
Table 4. Gene ontology processes.
Category Term Count Percentage P-value Benjamini
GO term biological function Regulation of transcription 55 15.8 8.60E  02 9.90E  01
GO term biological process Transcription 48 13.8 4.00E  02 9.90E  01
GO term biological process Regulation of transcription from RNA
polymerase II promoter
21 6 4.50E  02 9.90E  01
GO term biological process Immune response 20 5.7 2.50E  02 1.00E þ 00
GO term biological process Response to wounding 18 5.2 1.60E  02 1.00E þ 00
GO term biological process Vesicle-mediated transport 18 5.2 3.70E  02 1.00E þ 00
GO term biological process Defence response 18 5.2 5.40E  02 9.90E  01
GO term biological process Protein kinase cascade 12 3.4 7.80E  02 9.90E  01
GO term biological process Inﬂammatory response 11 3.2 7.40E  02 9.90E  01
GO term biological process Positive regulation of immune system process 10 2.9 3.00E  02 1.00E þ 00
GO term biological process Positive regulation of developmental process 10 2.9 7.20E  02 9.90E  01
GO term biological process Muscle organ development 9 2.6 4.10E  02 9.90E  01
GO term biological process Actin cytoskeleton organisation 9 2.6 5.20E  02 9.90E  01
GO term biological process Actin ﬁlament-based process 9 2.6 7.10E  02 9.90E  01
GO term biological process Protein maturation 8 2.3 6.00E  03 1.00E þ 00
GO term biological process Protein folding 8 2.3 3.10E  02 1.00E þ 00
GO term biological process Regulation of cytokine production 8 2.3 5.10E  02 9.90E  01
GO term biological process Positive regulation of lymphocyte activation 6 1.7 3.40E  02 1.00E þ 00
GO term biological process positive regulation of leukocyte activation 6 1.7 4.50E  02 9.90E  01
GO term biological process Protein processing 6 1.7 4.80E  02 9.90E  01
GO term biological process Positive regulation of cell activation 6 1.7 5.30E  02 9.90E  01
GO term biological process Immune effector process 6 1.7 9.90E  02 1.00E þ 00
GO term biological process Positive regulation of growth 5 1.4 6.30E  02 9.90E  01
GO term biological process Sphingolipid biosynthetic process 4 1.1 2.00E  02 1.00E þ 00
GO term biological process Membrane lipid biosynthetic process 4 1.1 2.50E  02 1.00E þ 00
GO term biological process Ceramide biosynthetic process 3 0.9 3.10E  02 1.00E þ 00
GO term biological process Membrane budding 3 0.9 3.50E  02 1.00E þ 00
GO term biological process Sphingoid biosynthetic process 3 0.9 3.50E  02 1.00E þ 00
GO term biological process Antigen processing and presentation of peptide
antigen via MHC class I
3 0.9 3.90E  02 1.00E þ 00
GO term biological process Retrograde vesicle-mediated transport,
Golgi to ER
3 0.9 5.80E  02 9.90E  01
GO term biological process Multicellular organismal catabolic process 3 0.9 8.40E  02 9.90E  01
GO term biological process Collagen metabolic process 3 0.9 9.60E  02 1.00E þ 00
GO term biological process Antigen processing and presentation of peptide
antigen
3 0.9 9.60E  02 1.00E þ 00
GO term biological process Positive regulation of keratinocyte migration 2 0.6 5.50E  02 9.90E  01
GO term biological process Regulation of keratinocyte migration 2 0.6 5.50E  02 9.90E  01
GO term cellular component Endoplasmic reticulum lumen 6 1.7 2.30E  02 1.00E þ 00
GO term cellular component Cell surface 14 4 2.60E  02 9.80E  01
GO term cellular component Perinuclear region of cytoplasm 12 3.4 3.40E  02 9.60E  01
GO term cellular component Cell fraction 31 8.9 5.10E  02 9.70E  01
GO term cellular component Insoluble fraction 25 7.2 5.80E  02 9.60E  01
GO term cellular component Transcription factor complex 9 2.6 6.40E  02 9.50E  01
GO term cellular component Membrane fraction 24 6.9 6.70E  02 9.30E  01
GO term cellular component Intracellular organelle lumen 45 12.9 8.70E  02 9.60E  01
GO term molecular function Enzyme binding 22 6.3 4.90E  04 1.90E  01
GO term molecular function Complement binding 3 0.9 8.70E  03 8.50E  01
GO term molecular function Protein dimerisation activity 17 4.9 3.60E  02 1.00E þ 00
GO term molecular function Speciﬁc RNA polymerase II transcription
factor activity
4 1.1 3.60E  02 9.80E  01
GO term molecular function Ubiquitin-protein ligase activity 7 2 4.90E  02 9.90E  01
GO term molecular function Carbohydrate binding 12 3.4 5.00E  02 9.80E  01
GO term molecular function Protein kinase binding 7 2 5.00E  02 9.60E  01
GO term molecular function Ligase activity, forming carbon-nitrogen bonds 9 2.6 5.20E  02 9.50E  01
GO term molecular function Complement component C1q binding 2 0.6 5.40E  02 9.30E  01
GO term molecular function Acid-amino acid ligase activity 8 2.3 6.60E  02 9.50E  01
GO term molecular function RNA polymerase II transcription factor activity 9 2.6 6.90E  02 9.40E  01
GO term molecular function Small conjugating protein ligase activity 7 2 7.70E  02 9.50E  01
GO term molecular function Protein homodimerization activity 11 3.2 8.00E  02 9.40E  01
GO term molecular function ubiquitineubiquitin ligase activity 2 0.6 8.80E  02 9.40E  01
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using whole plaque specimens and individual RNA samples
on each array the heterogeneity of specimens meant that
when multiple testing correction was applied no signiﬁcant
values were detected. On the recommendation of the array
manufacturer, after omitting multiple testing correction our
gene list was placed in hierarchical order and top genes
used based on P-value. In view of this we looked at gene
clusters and pathways and not individual genes. This study
was meant to serve as a discovery study to provide genes
and pathways of interest for further large scale studies.
In conclusion, this study has identiﬁed genes with altered
expression which are involved in immune, inﬂammatory,
cell signalling and protein deﬁning processes between
histologically unstable and stable plaques within neurolog-
ically asymptomatic patients. Functional analysis of these
candidate genes will be needed to determine if the differ-
ential expression is a precursor to symptom onset. Once
validated, these genes may become targets for innovative
medical treatments in the future or (in conjunction with
novel US/MRI/PET imaging features or plasma biomarkers)
could help identify asymptomatic patients with histologi-
cally, unstable plaques that would beneﬁt from surgical
intervention. This work will require evaluation in experi-
mental models of unstable carotid plaque to separate cause
from effect.APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.ejvs.2012.11.006.CONFLICT OF INTEREST/FUNDING
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